Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.48 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.42 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | CFTR | P13569 | 1/20 | 0.42 |
| ▸ | AHR | P35869 | 7/20 | 0.42 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.42 |
| ▸ | CMA1 | P23946 | 1/20 | 0.42 |
| ▸ | F7 | P08709 | 1/20 | 0.42 |
| ▸ | LTA4H | P09960 | 1/20 | 0.42 |
| ▸ | F3 | P13726 | 1/20 | 0.42 |
| ▸ | TYR | P14679 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | RAD51 | Q06609 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8957501 | 0.91 | GPR84 (0.46) | GPR84CYP2A6CSNK2A1MEN1POLB | |
| SCHEMBL30741638 | 0.88 | CFTR (0.47) | GPR84CYP2A6CSNK2A1MEN1POLB | |
| SCHEMBL13285075 | 0.86 | GPR84 (0.44) | GPR84CYP2A6CSNK2A1MEN1POLB | |
| SCHEMBL14616743 | 0.86 | GPR84 (0.44) | GPR84CYP2A6CSNK2A1MEN1POLB | |
| SCHEMBL8957446 | 0.84 | GPR84 (0.62) | GPR84CYP2A6CSNK2A1MEN1POLB | |
| SCHEMBL8957459 | 0.84 | CSNK2A1 (0.50) | GPR84CYP2A6CSNK2A1MEN1POLB | |
| SCHEMBL396029 | 0.84 | GPR84 (0.42) | GPR84CYP2A6CSNK2A1MEN1POLB | |
| SCHEMBL29358322 | 0.84 | GPR84 (0.42) | GPR84CYP2A6CSNK2A1MEN1POLB | |
| SCHEMBL8529327 | 0.84 | CSNK2A1 (0.55) | GPR84CYP2A6CSNK2A1MEN1POLB | |
| SCHEMBL26824096 | 0.84 | GPR84 (0.62) | GPR84CYP2A6CSNK2A1MEN1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11858945-B2 | Alkyne-containing antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-20230159545-A1 | ALKYNE-CONTAINING ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2023-05-25 | — | — | US | disclosed |
| US-10988466-B2 | Heterocyclic derivatives useful as SHP2 inhibitors | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2021-04-27 | — | — | US | disclosed |
| US-10987348-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-04-27 | — | — | US | disclosed |
| US-20200392128-A1 | NOVEL HETEROCYCLIC DERIVATIVES USEFUL AS SHP2 INHIBITORS | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2020-12-17 | — | — | US | disclosed |
| US-10662192-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2020-05-26 | — | — | US | disclosed |
| US-20190144450-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-05-16 | — | — | US | disclosed |
| US-20190076419-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-03-14 | — | — | US | disclosed |
| US-10022352-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2018-07-17 | — | — | US | disclosed |
| US-9974781-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2018-05-22 | — | — | US | disclosed |
| US-20100168094-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-07-01 | — | — | US | disclosed |
| US-20090298876-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-12-03 | — | — | US | disclosed |
| US-20090246820-A1 | COMPOUNDS USEFUL IN CFTR ASSAYS AND METHODS THEREWITH | VERTEX PHARMACEUTICALS INCORPORATED | 2009-10-01 | — | — | US | disclosed |
| US-20090227797-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-09-10 | — | — | US | disclosed |
| US-7495103-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-02-24 | — | — | US | disclosed |
| US-20080071095-A1 | Cystic fibrosis transmembrane conductance | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-03-20 | — | — | US | disclosed |
| US-20070264196-A1 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED | 2007-11-15 | — | — | US | disclosed |
| US-20070105884-A1 | Opiate analogs selective for the delta-opioid receptor | WELSH WILLIAM J | 2007-05-10 | — | — | US | disclosed |
| US-7164021-B2 | Opiate analogs selective for the δ-opioid receptor | THE CURATORS OF THE UNIVERSITY OF MISSOURI (US) | 2007-01-16 | — | — | US | disclosed |
| US-7164021-B2 | Opiate analogs selective for the δ-opioid receptor | THE CURATORS OF THE UNIVERSITY OF MISSOURI (US) | 2007-01-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190144450-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | GPR84 522/4885CYP2A6 1793/4885CSNK2A1 4180/4885 |
| US-20090227797-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | GPR84 522/4885CYP2A6 1793/4885CSNK2A1 4180/4885 |
| US-10987348-B2 | Modulators of ATP-binding cassette transporters | CFTR, ABCB1, ABCC2 | GPR84 409/4885CYP2A6 1094/4885CSNK2A1 4288/4885 |
| US-20070105884-A1 | Opiate analogs selective for the delta-opioid receptor | OPRM1, OPRD1, OPRK1 | GPR84 154/4885CYP2A6 1637/4885CSNK2A1 1177/4885 |
| US-20070264196-A1 | Modulators of ATP-binding cassette transporters | CFTR, ABCB1, ABCC2 | GPR84 469/4885CYP2A6 1700/4885CSNK2A1 3997/4885 |
| US-10662192-B2 | Modulators of ATP-binding cassette transporters | CFTR, ABCB1, ABCC2 | GPR84 522/4885CYP2A6 1793/4885CSNK2A1 4180/4885 |
| US-20190076419-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | GPR84 409/4885CYP2A6 1094/4885CSNK2A1 4288/4885 |
| US-10988466-B2 | Heterocyclic derivatives useful as SHP2 inhibitors | PTPRJ, PTPN5, PTPN1 | GPR84 2711/4885CYP2A6 3159/4885CSNK2A1 306/4885 |
| US-20090298876-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | GPR84 522/4885CYP2A6 1793/4885CSNK2A1 4180/4885 |
| US-20200392128-A1 | NOVEL HETEROCYCLIC DERIVATIVES USEFUL AS SHP2 INHIBITORS | PTPN5, PTPN1, PTPRJ | GPR84 2372/4885CYP2A6 3126/4885CSNK2A1 325/4885 |
| US-20100168094-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, ABCB1, ABCC2 | GPR84 229/4885CYP2A6 2703/4885CSNK2A1 4033/4885 |
| US-11858945-B2 | Alkyne-containing antiviral agents | ACE, SARS1, ACE2 | GPR84 1931/4885CYP2A6 1347/4885CSNK2A1 743/4885 |
| US-20080071095-A1 | Cystic fibrosis transmembrane conductance | CFTR, ABCB1, ABCC1 | GPR84 370/4885CYP2A6 3185/4885CSNK2A1 3946/4885 |
| US-10022352-B2 | Modulators of ATP-binding cassette transporters | CFTR, ABCB1, ABCC2 | GPR84 409/4885CYP2A6 1094/4885CSNK2A1 4288/4885 |
| US-20230159545-A1 | ALKYNE-CONTAINING ANTIVIRAL AGENTS | ACE, SARS1, ACE2 | GPR84 1931/4885CYP2A6 1347/4885CSNK2A1 743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.